NeoGenomics Inc (NEO)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.99B
Last updated: Nov 17, 2026 at 4:26 PM ET
NeoGenomics Inc (NEO) Stock Chart
NeoGenomics (NEO) has a latest price of $15.25 on Nov 17, 2026, 24.3% below its 52-week high of $20.15. Its price rose 47.5% over the past 12 months. The month-end price rose 115.6% over the 10 years through Oct 2026, a compound annual rate of 8.0%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $53.84 in Dec 2020 and its lowest $4.84 in Jul 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart NEO with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for NEO.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 8.4%, and over 6 months it rose 81.8%. The month-end price rose 24.0% over the 3 years through Oct 2026, a compound annual rate of 7.4%.
| Period | Change |
|---|---|
| 1 month | -7.1% |
| 3 months | -8.4% |
| 6 months | +81.8% |
| 12 months | +47.5% |
| 12 months, with dividends | +47.5% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +24.0% | +7.4% |
| 5 years | -62.2% | -17.7% |
| 10 years | +115.6% | +8.0% |
Price by Year
Its best calendar year was 2019, when the price rose 132.0%, and its weakest was 2022, when it fell 72.9%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $17.38 | +47.8% |
| 2025 | $11.76 | -28.6% |
| 2024 | $16.48 | +1.9% |
| 2023 | $16.18 | +75.1% |
| 2022 | $9.24 | -72.9% |
| 2021 | $34.12 | -36.6% |
| 2020 | $53.84 | +84.1% |
| 2019 | $29.25 | +132.0% |
| 2018 | $12.61 | +42.3% |
| 2017 | $8.86 | +3.4% |
Trading Range
The price is 12.7% below its 50-day average of $17.46 and 17.1% above its 200-day average of $13.02.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $15.25 | |
| 52-week high | $20.15 | -24.3% |
| 52-week low | $7.07 | +115.7% |
| 50-day average | $17.46 | -12.7% |
| 200-day average | $13.02 | +17.1% |
Price Risk
Over 3 years, its largest fall from a peak was 76.7%.
| Measure | Value |
|---|---|
| 1-year beta | 1.15 |
| Largest fall, 1 year | -45.6% |
| Largest fall, 3 years | -76.7% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About NEO
What is NEO's 1-year price change?
NeoGenomics's price rose 47.5% over the past 12 months. With dividends included, the 12-month total return was 47.5%.
What is NEO's 5-year price change?
NeoGenomics's month-end price fell 62.2% over the 5 years through Oct 2026, a compound annual decline of 17.7%. These figures leave out dividends.
What is NEO's 52-week high and low?
NeoGenomics's 52-week high is $20.15 and its 52-week low is $7.07. Its latest price of $15.25 on Nov 17, 2026 is 24.3% below the high.
What is NEO's beta?
NeoGenomics's 1-year beta against the S&P 500 is 1.15, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 45.6%.
Is the NEO chart free?
Yes. Advanced Charting for NEO is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
NEO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts